Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03896685
Other study ID # MSF ERB-1761
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date April 6, 2020
Est. completion date November 2024

Study information

Verified date July 2023
Source Médecins Sans Frontières, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.


Description:

This is a Phase III, randomized, controlled, open-label, multi-country trial evaluating the efficacy of new combination regimens for treatment of fluoroquinolone-resistant MDR-TB. Regimens examined combine newly approved drugs bedaquiline and delamanid with existing drugs known to be active against Mycobacterium tuberculosis (linezolid and clofazimine). The study will enroll in parallel across 1 experimental and 1 standard-of-care control arms, in a 2:1 ratio. Randomization will be stratified by country and extent-of-TB-disease phenotype. In the experimental arm, treatment will be for 24 or 39 weeks; duration will be assigned according to extent-of-TB-disease phenotype and treatment response. In the control arm, treatment will be delivered according to WHO guidelines (and local practice); duration will be variable. Trial participation in both arms will last at least until Week 73, and up to Week 104. Non-inferiority will be established for the experimental arm if the lower bound of the one-sided 97.5% confidence interval around the difference in favorable outcome between the control and experimental arms is greater than or equal to -12%.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 323
Est. completion date November 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: 1. Has documented pulmonary tuberculosis due to strains of M. tuberculosis resistant to rifampin (RIF) and not susceptible to fluoroquinolones, according to a validated rapid molecular test. Patients with RIF-resistant TB who are unable to tolerate fluoroquinolones (history of severe adverse events, allergies, hypersensitivity) are also eligible, regardless of resistance/susceptibility to fluoroquinolones; 2. Is =15 years of age; 3. Is willing to use contraception: pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilized must agree to use contraception unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms; 4. Provides informed consent for study participation; additionally a legal representative of patients considered minor per local laws should also provide consent; 5. Lives in a dwelling that can be located by study staff and expects to remain in the area for the duration of the study. Exclusion Criteria: 1. Has known allergies or hypersensitivity to any of the investigational drugs; 2. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant; 3. Is unable to comply with treatment or follow-up schedule; 4. Has any condition (social or medical) which, in the opinion of the site principal investigator, would make study participant unsafe; 5. a. Has had exposure (intake of the drug for 30 days or more) in the past five years to bedaquiline, delamanid, linezolid, or clofazimine, or has proven or likely resistance to bedaquiline, delamanid, linezolid, or clofazimine (e.g., household contact of a DR-TB index case who died or experienced treatment failure after treatment containing bedaquiline, delamanid, linezolid, or clofazimine or had resistance to one of the listed drugs); exposure to other anti-TB drugs is not a reason for exclusion. b. Has received second-line drugs for 15 days or more prior to screening visit date in the current MDR/RR-TB treatment episode. Exceptions include: 1. patients whose treatment has failed according to the WHO definition and who are being considered for a new treatment regimen; 2. patients starting a new treatment regimen after having been "lost to follow-up" according to the WHO definition and, 3. patients in whom treatment failure is suspected (but not confirmed according to WHO definition), who are being considered for a new treatment regimen, and for whom the Clinical Advisory Committee (CAC) consultation establishes eligibility. 6. Has one or more of the following: • Hemoglobin =7.9 g/dL; • Uncorrectable electrolytes disorders: - Total Calcium <7.0 mg/dL (1.75 mmol/L); - Potassium <3.0 mEq/L (3.0 mmol/L) or =6.0 mEq/L (6.0 mmol/L); - Magnesium <0.9 mEq/L (0.45 mmol/L); - Serum creatinine >3 x ULN; - Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) =3 x ULN; - Total bilirubin =3 x ULN; Unless otherwise specified, Grade 4 result as defined by the MSF Severity Scale on any of the screening laboratory tests. 7. Has cardiac risk factors defined as: - An arithmetic average of the two ECGs with highest QTcF intervals of greater than or equal to 450 ms. Retesting to reassess eligibility will be allowed using an unscheduled visit during the screening phase; - Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome); - Electrocardiographic evidence of either: - Complete left bundle branch block or right bundle branch block; OR - Incomplete left bundle branch block or right bundle branch block and QRS complex duration greater than or equal to 120 msec on at least one ECG; • Having a pacemaker implant; - Congestive heart failure; - Evidence of second or third degree heart block; - Bradycardia as defined by sinus rate less than 50 bpm; - Personal or family history of Long QT Syndrome; - Personal history of arrhythmic cardiac disease, with the exception of sinus arrhythmia; - Personal history of syncope (i.e. cardiac syncope not including syncope due to vasovagal or epileptic causes). 8. Concurrent participation in another trial of any medication used or being studied for TB treatment, as defined in cited documents. 9. Is taking any medication that is contraindicated with the medicines in the trial regimen which cannot be stopped (with or without replacement) or requires a wash-out period longer than 2 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bedaquiline 100 MG
Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
Delamanid 50 MG Oral Tablet
Delamanid: 100 mg BID
Clofazimine 100 MG Oral Capsule
Clofazimine: 100 mg QD
Linezolid 600Mg Tab
Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
Control arm MDR-TB regimen, designed according to latest WHO guidelines
Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).

Locations

Country Name City State
India Aundh Chest Hospital Pune
Kazakhstan National Center for Tuberculosis Problems Almaty
Kazakhstan State Municipal Enterprise on the right of economic management "City Centre of Phthisiopulmonology" of Nur-sultan city's administration Nur-Sultan
Lesotho Partners In Health Lesostho Maseru
Pakistan The Indus Hospital Karachi
Pakistan Institute of Chest Disease, Kotri
Peru Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales Lima
Peru Centro de Investigación del Hospital Nacional Hipólito Unanue Lima
Vietnam Hanoi Lung Hospital Hanoi
Vietnam Pham Ngoc Thach Hospital Ho Chi Minh City

Sponsors (8)

Lead Sponsor Collaborator
Médecins Sans Frontières, France Epicentre, Harvard Medical School (HMS and HSDM), Institute of Tropical Medicine, Belgium, Interactive Research and Development, Partners in Health, Socios En Salud, Peru, University of San Francisco

Countries where clinical trial is conducted

India,  Kazakhstan,  Lesotho,  Pakistan,  Peru,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Week 73 Efficacy: Proportion of participants with favorable outcome at Week 73 Proportion of participants with favorable outcome at Week 73. A participant's outcome will be classified as favorable at Week 73 if the outcome is not classified as unfavorable, and one of the following is true:
The last two culture results are negative. These two cultures must be taken from sputum samples collected on separate visits, the latest between Week 65 and Week 73;
The last culture result (from a sputum sample collected between Week 65 and Week 73) is negative; and either there is no other post-baseline culture result or the penultimate culture result is positive due to laboratory cross contamination; and bacteriological, radiological and clinical evolution is favorable;
There is no culture result from a sputum sample collected between Week 65 and Week 73 or the result of that culture is positive due to laboratory cross contamination; and the most recent culture result is negative; and bacteriological, radiological and clinical evolution is favorable.
Week 73 after randomization
Secondary Week 104 Efficacy: Proportion of participants with favorable outcome at Week 104 Proportion of participants with favorable outcome at Week 104. A participant's outcome will be classified as favorable at Week 104 if the outcome is not classified as unfavorable, and one of the following is true:
The last two cultures are negative. These two cultures must be from sputum samples collected on separate visits, the latest between Week 97 and Week 104;
The last culture result (from a sputum sample collected between Week 97 and Week 104) is negative; and either there is no other post-baseline culture result or the penultimate culture result is positive due to laboratory cross contamination; and bacteriological, radiological and clinical evolution is favorable;
There is no culture result from a sputum sample collected between Week 97 and Week 104 or the result of that culture is positive due to laboratory cross contamination; and the most recent culture result is negative; and bacteriological, radiological and clinical evolution is favorable.
Week 104 after randomization
Secondary Early Treatment Response (culture conversion) Proportion of patients with culture conversion assessed in MGIT system (and LJ where possible): 2 consecutive negative cultures from specimens collected at 2 different visits; if there is a missing or contaminated culture between 2 negatives, the definition of conversion is still met;
Time to culture conversion: assessed in MGIT system (and LJ where possible): time from treatment initiation to first of 2 consecutive negative cultures; if there is a missing or contaminated culture between 2 negatives, the definition of conversion is still met;
Change in time to positivity (TTP) in MGIT over first 8 weeks.
Week 8 after randomization
Secondary Week 39 Efficacy: Proportion of participants with favorable outcome at Week 39 Proportion of participants with favorable outcome at Week 39. A participant's outcome will be classified as favorable at Week 39 if all culture results from samples collected between Week 36 and Week 39 are negative and the outcome is not classified as unfavorable.
A participant's outcome will be classified as unfavorable at Week 39 in case of:
In the experimental arm, addition or replacement of one or more drugs;
In the control arm, addition or replacement of two or more drugs;
Death from any cause;
At least one culture result (from a sample collected between Week 36 and Week 39) is positive;
The patient is not assessable because the last available culture result is from a sample collected before Week 36;
Week 39 after randomization
Secondary Week 73 Failure/Relapse Proportion of participants with treatment failure/relapse. A participant's outcome will be classified as failure/relapse at Week 73 if:
In an experimental arm, addition or replacement of one or more drugs;
In the control arm, addition or replacement of two or more drugs;
Initiation of a new MDR-TB regimen after the end of the allocated study regimen and before Week 73;
At least one of the last two cultures, the latest between Week 65 and 73, is positive in the absence of cross contamination;
The last culture result between Week 65 and 73 is negative; and: there is no other post-baseline culture result or the penultimate culture is positive due to cross contamination; and bacteriological, radiological or clinical evolution is unfavorable;
There is no culture result between Week 65 and 73 or it is positive due to cross contamination; and: the most recent culture is negative; and bacteriological, radiological or clinical evolution is unfavorable.
Week 73 after randomization
Secondary Week 104 Failure/Relapse Proportion of participants with treatment failure/relapse. A participant's outcome will be classified as failure/relapse at Week 104 if:
In an experimental arm, addition or replacement of one or more drugs;
In the control arm, addition or replacement of two or more drugs;
Initiation of a new MDR-TB treatment regimen after the end of the allocated study regimen and before Week 104;
At least one of the last two cultures, the latest between Week 97 and 104, is positive in the absence of cross contamination;
The last culture result between Week 97 and 104 is negative; and: there is no other post-baseline culture result or the penultimate culture is positive due to cross contamination; and bacteriological, radiological or clinical evolution is unfavorable;
There is no culture result between Week 97 and 104 or it is positive due to cross contamination; and: the most recent culture is negative; and bacteriological, radiological or clinical evolution is unfavorable.
Week 104 after randomization
Secondary Week 73 Survival At 73 weeks, the proportion of patients who died of any cause Week 73 after randomization
Secondary Week 104 Survival At 104 weeks, the proportion of patients who died of any cause Week 104 after randomization
Secondary Week 73 AEs and SAEs The proportion of participants with grade 3 or greater AEs and serious adverse events (SAEs) of any grade by 73 weeks Week 73 after randomization
Secondary Week 104 AEs and SAEs The proportion of participants with grade 3 or greater AEs and serious adverse events (SAEs) of any grade by 104 weeks Week 104 after randomization
Secondary Week 73 AESIs The proportion of participants with adverse events of special interest (AESIs) by 73 weeks Week 73 after randomization
Secondary Week 104 AESIs The proportion of participants with adverse events of special interest (AESIs) by 104 weeks Week 104 after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2